The short answer
Axon Enterprise (AXON) remains doubtful for investors who avoid weapons or certain surveillance activity, although its known financial ratios pass the examined screens. Axon sells TASER conducted-energy devices, body cameras, drones, counter-drone equipment, emergency-communications tools and cloud software. The current filing quantifies those product lines, but it cannot decide whether every TASER or law-enforcement dollar is prohibited under every scholarly approach.
This is a reproducible research screen, not a fatwa or investment recommendation. Scholars can differ on less-lethal weapons, public-safety technology, government end use, surveillance, AI deployment and the distinction between a product category and a prohibited business activity.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-13.
1,750 / 7,066.849
736.973 / 7,066.849
1,133.519 / 7,066.849
10.611 / 807.345
- Financial
- Pass
- Overall
- Incomplete
Debt is 24.76%, identifiable liquidity is 10.43%, receivables plus cash are 16.04% and disclosed interest income is 1.31%; all examined financial ratios pass. The business-activity classification remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt, identifiable liquidity and receivables plus cash pass the examined total-assets limits. The business-activity evidence remains incomplete; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Incomplete
Debt is 24.76% and identifiable conventional liquidity is 10.43%, below the examined 33% limits. This is a calculation against SAC ratios, not an official SAC classification of a U.S.-listed security; the business screen remains unresolved.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Axon describes itself as a provider of public-safety technology solutions. Its Q1 2026 revenue consists of connected devices—including TASER conducted-energy devices, personal sensors and platform solutions such as cameras, drones and counter-drone equipment—and software and services. The software and emergency-communications activity can be permissible, while weapons, law-enforcement, surveillance and dual-use activity require a school- and context-specific assessment.
Limitation: The filing disaggregates revenue by product and service offering but does not provide a universally accepted prohibited-revenue numerator for weapons, law-enforcement, government, military, surveillance, counter-drone or AI use. The $232.853 million TASER line is quantifiable, but its Sharia classification is disputed rather than an objective zero-or-one category.
Purification
Axon separately discloses 10.611 of interest income, or 1.31% of quarterly net sales, and it passes the examined FTSE income threshold. However, the disputed weapons and law-enforcement business classification is not resolved by the filing, so this record does not prescribe a fixed purification amount.
Inputs, assumptions and primary sources
- Interest-bearing debt uses the gross principal of the 2030 and 2033 senior notes, 1,750, before the reported 19.013 debt-issuance-cost deduction. The remaining 2027 Notes were redeemed or converted during the quarter; long-term lease liabilities are not classified as interest-bearing notes in this input.
- Cash uses the balance-sheet cash and cash equivalents of 458.921. Short-term investments of 260.000 and marketable securities of 18.052 are included as identifiable investment securities; restricted cash of 12.235 and strategic investments of 838.243 are not added to the cash input or inferred into the securities numerator.
- Receivables use accounts and notes receivable of 674.598, net of the reported allowance. Contract assets are separately disclosed and are not added to the receivables input.
- Revenue uses net sales of 807.345 for the three months ended March 31, 2026. The filing reports TASER revenue of 232.853, Personal Sensors revenue of 108.751, Platform Solutions revenue of 111.217 and Software and Services revenue of 354.524.
- The filing separately reports interest income of 10.611 and interest expense of 28.643. Interest income is 1.31% of quarterly net sales; interest expense is not netted against that disclosed income numerator.
- TASER revenue is directly disclosed, but whether conducted-energy devices constitute a prohibited business activity is a disputed scholarly and ethical classification. It is therefore not entered as a universal prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Current quantitative screen
The calculations above use Axon's official filing (Form 10-Q for the quarter ended March 31, 2026). Amounts are in USD millions and use total assets as the denominator so the inputs can be reproduced from the filing.
- Interest-bearing debt / assets: 24.76%, using $1.750 billion of gross senior-note principal. The remaining 2027 Notes were redeemed or converted during the quarter.
- Cash plus identifiable investment securities / assets: 10.43%, using cash of $458.921 million, short-term investments of $260.000 million and marketable securities of $18.052 million.
- Receivables plus cash / assets: 16.04%, using net accounts and notes receivable of $674.598 million and the balance-sheet cash amount.
- Interest income / revenue: 1.31%, using separately reported interest income of $10.611 million against quarterly net sales of $807.345 million. Interest expense is not netted against that income numerator.
The FTSE Yasaar, MSCI total-assets and Malaysia SAC financial-ratio calculations all pass their known financial checks. The overall results remain incomplete because the filing does not provide a universally accepted prohibited-revenue allocation for TASER, surveillance, government or dual-use activity. Market-cap-denominator methods are not calculated because this site does not store a licensed, reproducible historical market-cap series for the filing date.
What Axon does
Axon describes itself as a provider of public-safety technology solutions. For the quarter ended March 31, 2026, the filing reports $232.853 million of TASER revenue, $108.751 million from Personal Sensors, $111.217 million from Platform Solutions and $354.524 million from Software and Services, for $807.345 million of net sales.
The filing says TASER includes conducted-energy-device handles, cartridges and related extended warranties. Personal Sensors primarily includes body cameras and accessories. Platform Solutions primarily includes fleet and fixed cameras, drones, counter-drone equipment and virtual-reality training hardware. Software and Services includes cloud and other public-safety workflows. This product mix is why a one-word answer is not enough.
Qualitative considerations
- TASER weapons: TASER generated $232.853 million, approximately 28.84% of Q1 net sales. The filing describes Axon as a manufacturer of weapons and other law-enforcement tools and reports product-liability claims involving alleged wrongful death or personal injury. Some scholars permit less-lethal public-safety tools; others apply a stricter weapons exclusion.
- Surveillance and privacy: body cameras, fleet video, fixed cameras, drones, evidence platforms and AI can support accountability and safety, but they also raise questions about consent, retention, due process, bias, access controls and misuse. The current shareholder materials say Axon Vision does not use facial recognition; that does not resolve every broader AI and video-governance concern.
- Customer and end use: Axon reports expansion into corrections, U.S. federal and enterprise customers, but does not quantify revenue by government, military, law-enforcement or civilian end use. The old fixed military-contract percentage is therefore not repeated.
- Carbyne acquisition: Axon acquired the remaining 89.3% of Carbyne in February 2026 for approximately $549.7 million of cash paid. The cloud emergency-communications business is generally distinct from TASER, but integration and purchase-accounting changes should be monitored.
- Financial and reporting risk: the company holds investment securities and senior notes, reports separate interest income and interest expense, and says a material weakness in revenue-recognition controls remained under remediation as of March 31, 2026.
How the methodologies differ
Under the reproduced FTSE Yasaar calculation, the debt, liquidity, receivables-plus-cash and disclosed-income ratios pass, but the business activity remains incomplete. The MSCI total-assets and Malaysia SAC financial-ratio calculations also pass their known financial tests. None of these calculations resolves whether TASER or particular surveillance and law-enforcement contracts meet the business-activity standard a reader follows; they are not official index-membership claims or a universal scholarly ruling.
Bottom line
AXON is presented as doubtful because of its disclosed weapons and dual-use public-safety business, despite passing the known financial ratios. The main unresolved item is not the balance-sheet screen; it is how a scholar classifies TASER revenue, surveillance technology and customer end use.
If you are considering AXON, compare this evidence with the methodology and scholar you follow, monitor the next filing and avoid treating the financial pass as a blanket approval of the weapons or surveillance activities.
TASER and dual-use public-safety technology make the qualitative classification scholar-dependent.
Check another asset →